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Oral Presentations S229Voriconazole was given as prophylaxis in 44% of cases, 23% re-
ceived it empirically and 33% as therapy. 14 of the 19 children
treated therapeutically had aspergillosis (11 possible, 2 probable, 1
proven). Dosing was according to the summary of product character-
istics. For children\2 yrs the recommended dosage for 2-12 yrs was
used. Voriconazole was prescribed for a mean period of 63 days
(range 6-415). In 11% of cases the drug was stopped due to toxicity.
Therapeutic drug monitoring of voriconazole: An adequate
trough level was defined as 1-5 mg/ml. First measurement of trough
levels was after a median of 5 days.
Only in 8% of children\2 years an adequate level was reached at
initial dosing.
3 of 15 children between 2-7 yrs of age on recommended dosage
had adequate levels at initial dosing (20%); in children aged 7-12
yrs 83% had adequate initial levels if dosage was as recommended.
14/33 patients.2 yrs on recommended dose had voriconazole levels
below the limit of detection (\0.5 mg/ml). 9% of all patients had an
initial trough level . 5 mg/ml.
The mean dose (range) to reach adequate trough levels for chil-
dren\2 was: 365 mg oral (220-600) and 29.4 mg/kg i.v. (5.2-70).
For the age group 2-7 years adequate levels were reached with
a mean dose of 26.2 mg/kg i.v. (20.7-29.6). .12 years this was
17.6 mg/kg i.v. (11.9-19.6).
Intrapatient variability of levels on constant dosage was 0.7-3.5
fold.
Conclusion: We conclude that therapeutic drug monitoring is in-
dispensable for correct dosage of voriconazole. Dosage recommen-
dations for children need adjustment, especially in the \2 age
group. Intra patient variability is also a major concern and necesit-
tates continued level measurements. Patient characteristics that de-
termine pharmacokinetic variability need to be identified in future
studies.
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FLUDARABINE + EXPOSURE-TARGETED BUSULFAN IN CHILDREN WITH
MALIGNANT AND NON-MALIGNANT DISEASES: AN EFFECTIVE AND LOW
TOXIC REGIMEN
Boelens, J.J.1, Bartelink, I.2, Lindemans, C.A.1, Bierings, M.1 1UMC
Utrecht, Netherlands; 2UMC Utrecht, Netherlands
Background: Busulfan (Bu) as myeloablative agent is used in condi-
tioning regimens prior to HSCT. We recently found a clear associ-
ation between Bu-exposure and outcomes. Comparison studies in
adults showed a favorable toxicity profile for fludarabine+busulfan
(FludBu) compared to the conventional BuCy regimen.We recently
initiated a prospective study analysing the effectively of FluBu inmy-
eloid malignancies and all non-malignant indications in pediatrics.
We compared the outcomes with our Bu(-exposure targeted)/Cy/
(Mel) from a previous cohort (2005-2008).
Methods: Fludarabine 40mg/m2 was given in 1 hour prior to a 3
hour infusion of once daily busulfan. The target area under the curve
(AUC) for Bu was 75-95 mg*h/L (in total) in both groups. Bu dose
targeting, based on therapeutic drug monitoring was performed be-
fore the second dose. Primary endpoint was event free survival (EFS)
and survival. Secondary endpoints were acute graft-versus-host dis-
ease (aGvHD), neutropenic period and the number of erythrocytes
and thrombocytes transfusions. A risk factor analysis was performed
using univariable and multivariable COX regression.
Results: 100 patients were included: 65 unrelated-CBT, 22 a MSD
and 13 a MUD. 52 patients were included in the FludBu group (me-
dian follow up 244 days; range 22-769) and 48 in the BuCy(Mel)
group (1015 days; range 6-2085). The median exposure of busulfan
was 88 (81-94)mg*h/L inFluBu and82 (74-100)mg*h/L inBuCy(Mel).
The groups were comparable regarding age, cell source, gender, in-
dication for BMT and match-grade. The probability on EFS in
FludBu and BuCy(Mel) was 74+/-6% and. 70+/-7% (NS), resp.
No difference in aGvHD ($grade 2: 20 vs.28%) was found. A trend
to a lower ‘‘non-relapse mortality’’ was found in the FluBu group
7+/-4% vs. 19+/-6% (p 5 0.08). The period of neutropenia was
median 11 in the FludBu compared to 20.5 in BuCy(Mel) (HR
0.38, p 5 0.05, CI95% 0.20-0.75). The median number of erythro-
cytes transfusion was 1 (range 1-13) in the FludBu group and 5 (0-22)
in the BuCy(Mel) group (p 5 0.02) and thrombocyte transfusions
4 (range 0-33) vs 10 (range 2-44; p 5 0,02). Less VOD was seen in
BuFlu 3% vs. 22% (p 5 0.01).Conclusion: Bu with a total target AUC of 75-95mg*h/l in combi-
nation with Flud showed to be an effective and low toxic regimen in
comparison to BuCy(Mel). A shorter neutropenic period and a lower
number of transfusions were needed in FludBu. FludBu as reduced
toxicity regimen showed promising results.72
UNRELATED BONE MARROW TRANSPLANTATION (UBMT) FOR CHIL-
DREN AND ADOLESCENTS WITH FANCONI ANEMIA (FA) USING CYCLO-
PHOPHAMIDE, FLUDARABINE AND RABBIT ATG: ANALYSIS OF 33
PATIENTS TRANSPLANTED AT A SINGLE INSTITUTION
Bonfim, C., Ribeiro, L., Loth, G., Bitencourt, M., Kanaan, S.N.,
Koliski, A., Funke, V., Pilonetto, D., Zanis-Neto, J., Pasquini, R. Federal
University of Parana, Curitiba, PR, Brazil
FA is a rare disease characterized by progressive bonemarrow fail-
ure, congenital anomalies and a striking predisposition to cancer.
HSCT is the only treatment able to cure the hematological compli-
cations related to this disease. In the absence of a fully matched re-
lated donor, the use of an unrelated donor is recommended but is
still associated with an increased rate of rejection and GVHD. Ob-
jective: Analyze the outcome of 33 pts with FA submitted to an
UBMT using CY+FLU+rATG in the conditioning regimen.
Patients and Methods: Period: 02/02 - 02/11, Age 5-18s (M:
10years) Sex: 17F/16M; Preparatory regimen: CY60mg/kg +
FLU125mg/m2 + rATG 4-6mg/kg; GVHD prophylaxis: Cyclo-
sporine and methotrexate. Stem cell source: bone marrow. All pts
and donors were HLA typed at least for low-resolution class I (locus
A, B, C) and high resolutionDRB1. 29pts were fully compatible (8/8)
and 4pts had one or two mismatches.
Results: 26 pts are alive between 8 months and 8ys days after BMT
(M: 2,7ys) with an overall survival (OS) of 79% in 3 years. 32 pts sur-
vived more than 28 days and were evaluated for engraftment. 3 pts
had only neutrophilic engraftment and all died between days +30
and +117 post BMT. One pt had primary graft failure (mismatch
in locus C) and received a 2nd UBMT (alive and well 4.8 ys after
UBMT). No late rejection occurred in this group of pts. Early com-
plications: mucositis grade III -IV: 75%. Moderate to severe arterial
hypertension: 70%. No pt developed severe hepatic sinusoidal syn-
drome. Hemorrhagic cystitis:7pts. Acute GVHD grade II-IV oc-
curred in 12/31 evaluable pts while chronic GVHD occurred in
11/26 evaluable pts (limited: 6pts; extensive: 5pts). Seven pts died be-
tween 20-117 days post UBMT (M: 50 days). Cumulative incidence
of TRM at 100 days was 18%. Causes of death were generally related
to infection (bacterial or fungal) or GVHD complications. Pts under
10 years had an excellent survival (94%) as well as those with fully
compatible donors (86%).
Conclusions:The results fromUBMT in FA have improved consid-
erably during the past few years. In this study, pts under the age of 10
had an excellent survival, equal to the one observed in pts with fully
matched related donors. Early referral, the use of conditioning reg-
imen containing fludarabine and the possibility of finding well
matched unrelated donors (65% of them found in the Brazilian reg-
istry) may have contributed for the success of this protocol.73
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS
WITH WISKOTT ALDRICH SYNDROME (WAS): ANALYSIS OF 36 CHIL-
DREN TRANSPLANTED IN A SINGLE INSTITUTION
Bonfim, C.1, Koliski, A.1, Ribeiro, L.1, Loth, G.1, Toassa Gomes, R.1,
Pasquini, R.1, Marinho, D.1, Kanaan, S.N.1, Cat, I.2, Zanis-Neto, J.1
1Federal University of Parana, Curitiba, PR, Brazil; 2Federal University
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WAS is a rare X-linked disease characterized by recurrent infec-
tions, eczema, thrombocytopeniawith small platelets andan increased
predisposition to autoimmunity and lymphoid malignancies. HSCT
is the only treatment with the possibility of cure.
Objective: Retrospective analysis of 36pts with WAS submitted to
HSCT at a single institution.
Patients andMethods: 36 boys; age: 0.9-14 ys (M: 2 ys), period: 04/
1992 05/2011. The majority of pts had severe manifestations of the
